T1	Participants 74 106	granulocytopenic cancer patients
T2	Participants 108 294	European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group
T3	Participants 299 373	total of 747 febrile granulocytopenic patients with cancer were randomized
